NCT05199090View on ClinicalTrials.gov

Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM

PHASE2TerminatedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

February 10, 2022

Primary Completion Date

May 11, 2023

Study Completion Date

May 11, 2023

Conditions
Obesity
Interventions
DRUG

MBL949

subcutaneous injections administered for 14 weeks

DRUG

Placebo

Placebo Comparator to MLB949

Trial Locations (4)

28557

Novartis Investigative Site, Morehead City

33135

Novartis Investigative Site, Miami

37920

Novartis Investigative Site, Knoxville

75230

Novartis Investigative Site, Dallas

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY